Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Sponsor: Memorial Sloan Kettering Cancer Center
Summary
This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.
Official title: Phase II Study to Examine Precision Radiation in Patients With Pathogenic Mutations in ATM
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2021-08-11
Completion Date
2027-08
Last Updated
2026-05-11
Healthy Volunteers
No
Conditions
Interventions
Palliative radiotherapy
Initial cohort (stage 1) of patients will receive 4Gy x 2. They will be re-evaluated at 2 and 6 months (+/- 2 weeks). Accounting for anticipated survival times of these patients, we expect to have 12 evaluable patients from 20 enrolled patients. For stage 2 dose reduction will be explored across two palliative regimens, with timepoint for local failure adjusted accordingly.
Locations (7)
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (All protocol activities)
Montvale, New Jersey, United States
Memorial Sloan Kettering Commack (All protocol activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States
Memorial Sloan Kettering Nassau (All protocol activities)
Uniondale, New York, United States